SCHEMBL3423396

SCHEMBL3423396

N#Cc1c(NC(=O)CCC2CCCCC2)sc2c1CCN(C(=O)Cn1ccnc1)C2

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 6/20 0.44
▸ KMT2A Q03164 6/20 0.44
▸ MAPK10 P53779 2/20 0.43
▸ MAPK9 P45984 1/20 0.43
▸ L3MBTL1 Q9Y468 3/20 0.42
▸ ESR2 Q92731 5/20 0.42
▸ POLB P06746 2/20 0.42
▸ ALDH1A1 P00352 4/20 0.42
▸ KDM4E B2RXH2 3/20 0.42
▸ USP2 O75604 1/20 0.42
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4508669 0.93 MAPK10 (0.48) MEN1KMT2AMAPK10MAPK9L3MBTL1
SCHEMBL3418594 0.84 MEN1 (0.53) MEN1KMT2AMAPK10MAPK9L3MBTL1
SCHEMBL3419611 0.84 MEN1 (0.49) MEN1KMT2AMAPK10MAPK9L3MBTL1
SCHEMBL3423269 0.83 MEN1 (0.57) MEN1KMT2AL3MBTL1POLBALDH1A1
SCHEMBL3420744 0.83 MEN1 (0.49) MEN1KMT2AMAPK10MAPK9L3MBTL1
SCHEMBL3421661 0.83 MAPK9 (0.49) MEN1KMT2AMAPK10MAPK9L3MBTL1
SCHEMBL4056323 0.82 MEN1 (0.53) MEN1KMT2AL3MBTL1ESR2POLB
SCHEMBL3422930 0.81 MEN1 (0.53) MEN1KMT2AMAPK10MAPK9L3MBTL1
SCHEMBL13676727 0.81 MAPK10 (0.45) MEN1KMT2AMAPK10MAPK9L3MBTL1
SCHEMBL3420764 0.81 MAPK10 (0.45) MEN1KMT2AMAPK10MAPK9L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090258873-A1 Novel tetrahydropyridothiophenes PEKARI KLAUS 2009-10-15 — — US claimed
US-20080206258-A1 Novel Tetrahydropyridothiophenes NYCOMED GMBH (DE) 2008-08-28 — — US claimed
EP-1896484-A2 TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER Nycomed GmbH (DE) 2008-03-12 — — EP claimed
WO-2006125813-A2 TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER NYCOMED GMBH (DE) 2006-11-30 — — WO claimed
US-7714136-B2 Tetrahydropyridothiophenes 4SC AG (DE) 2010-05-11 — — US disclosed
US-7714136-B2 Tetrahydropyridothiophenes 4SC AG (DE) 2010-05-11 — — US disclosed
US-20090258873-A1 Novel tetrahydropyridothiophenes PEKARI KLAUS 2009-10-15 — — US disclosed
US-20090258873-A1 Novel tetrahydropyridothiophenes PEKARI KLAUS 2009-10-15 — — US disclosed
US-20090258873-A1 Novel tetrahydropyridothiophenes PEKARI KLAUS 2009-10-15 — — US disclosed
US-20080206258-A1 Novel Tetrahydropyridothiophenes NYCOMED GMBH (DE) 2008-08-28 — — US disclosed
US-20080206258-A1 Novel Tetrahydropyridothiophenes NYCOMED GMBH (DE) 2008-08-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080206258-A1 Novel Tetrahydropyridothiophenes BAX, BCL2, CCAR2 MEN1 4691/4885KMT2A 2644/4885MAPK10 1273/4885
US-20090258873-A1 Novel tetrahydropyridothiophenes BAX, BCL2, CCAR2 MEN1 4735/4885KMT2A 2418/4885MAPK10 1331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback